EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Xconomy Q&A: WA Gov. Inslee on Education, Life Sciences, Climate, R&D

Xconomy Seattle — 

Before Washington Gov. Jay Inslee and state legislators can even think about renewing or expanding research and development incentives for innovation industries, they need to find a way to fill a hole in the state budget on the order of $5 billion over the next four years.

But in an interview with Xconomy on Friday, Inslee, a Democrat who campaigned on combating climate change, hinted at a potential solution in which a state cap-and-trade system to limit greenhouse gas emissions could help raise revenues to adequately fund K-12 education, as the Legislature has been ordered to do by the state Supreme Court in its McCleary decision.

“If you have to raise revenues, why not do it in a way that’s going to make your air healthier and reduce the threats of asthma and ocean acidification, and there is a way to do that,” Inslee told Xconomy after addressing the 2014 Governor’s Life Science Summit. “So I think legislators—over time, as they start to come to terms with how large the fiscal challenge is—may open their minds to, you know, solving two problems with one solution.”

The upcoming election, in which every state House seat and about half of the Senate is up for grabs, is obviously a wild card. Inslee acknowledged that passing carbon regulations of any kind would be much easier if Democrats retained control of the House and took back the state Senate.

He was cautious about revealing any specific strategies for resurrecting the state’s 20-year-old research and development tax credit and sales tax deferral, a top priority for technology companies across the state that legislators failed to renew. (It expires Jan. 1, 2015.) Likewise, he expressed strong support for the Life Sciences Discovery Fund, which he protected from defunding earlier this year with a veto, but could not make any guarantees.

“People know that I think investment in R&D is critical to our future and is one of the best investments we can make, so we’re going to look at that,” Inslee said. “But again, it has to be in a context of being able to raise revenue—total, from the total package—to go into schools, because that’s a necessity. We’re under court order to do that. It’s a judicial requirement. And more importantly, it’s a requirement for our grandkids and our kids.”

Inslee began his address to the life sciences meeting, which drew about 700 people, on a very personal note.

“Let’s be clear about what this industry produces. It does not produce widgets. It does not produce aluminum. It produces productive life itself,” said Inslee, whose father, Frank Inslee, passed away last week at 88. “This is not an abstraction to me.”

Inslee said his father enjoyed a vibrant, productive life in his final years, despite illness, because “somebody was optimistic enough to create some of these medicines that kept him going. I want to thank you for your industry that gave my family some extra few years of great life with my Dad.”

Inslee said he wants Washington to become “the global leader in life science innovation and healthcare delivery by the year 2025,” echoing aspirations of leaders of the Washington Biotechnology and Biomedical Association (WBBA), which is marking its 25th year.

But there’s a mixed picture for biotech in Washington state today. Chris Rivera, WBBA president and CEO, said there have been more than 50 investments, partnership, or collaboration deals involving Washington companies thus far this year, bringing some $1.1 billion to the state, compared with about $800 million in 2013. (Much of that capital has flowed to one company: Juno Therapeutics, which quickly amassed $310 million in funding starting late last year.) There were a total of 34,200 direct jobs in the state’s life sciences industry in 2013, up more than 3,300 jobs since 2007.

But the Seattle biotech sector’s anchor tenant, Amgen, is leaving town. Novo Nordisk is changing its Seattle-area focus. And Washington’s financial support for life sciences, already modest compared to the likes of Massachusetts, California, New York, and Texas, is precarious thanks to the R&D tax credit expiration, and attacks on the Life Sciences Discovery Fund as lawmakers seek revenue for education anywhere they can.

Inslee broke the bad news on the state’s coming budget challenge: … Next Page »

Single PageCurrently on Page: 1 2 3